文献速递眼底病与葡萄膜炎

新生血管性年龄相关性黄斑变性抗血管内皮生长因子治疗的中断发生率及原因

Incidence and reasons for discontinuation of anti-VEGF treatment in neovascular age-related macular degeneration.
PubMed 文献 · Br J Ophthalmol · 2025-07-22

这项多中心回顾性研究分析了2019年1月至2021年12月间开始抗血管内皮生长因子(VEGF)治疗的新生血管性渗出性年龄相关性黄斑变性(AMD)初治患者,评估治疗中断的发生率、具体原因、随时间变化的概率及相关危险因素。结果显示655人(28.5%)中断了眼内注射抗VEGF治疗,临床决策是最常见的中断原因,且在治疗最初2年内更常见;视力较差增加因临床决策中断的风险,年轻患者更可能主动选择停止治疗,视力较好且离诊所较远的患者更可能转至其他诊所继续治疗。

要点

  • 655人(28.5%)中断了眼内注射抗VEGF治疗。
  • 临床决策是治疗中断最常见的原因,在治疗最初2年内更常见。
  • 视力较差增加因临床决策中断的风险,年轻患者更可能主动停止治疗。

核心结论

  • 抗VEGF治疗中断在新生血管性AMD患者中常见,中断原因不仅包括临床医生决策,还包括与患者健康和个人选择相关的因素。

研究设计与样本

  • 多中心回顾性研究,纳入2019年1月至2021年12月间开始抗VEGF治疗的初治新生血管性渗出性AMD患者。

主要发现

  • 655人(28.5%)中断了眼内注射抗VEGF治疗。
  • 在五类主要中断原因(患者违背医嘱自行决定、转至其他诊所继续治疗、临床决策、全身性疾病或死亡)中,临床决策是最常见的中断原因。
  • Kaplan-Meier曲线的定性评估提示,临床决策作为中断原因在治疗最初2年内出现频率更高。
  • 视力较差增加因临床决策中断的风险。
  • 年轻患者更可能主动选择停止抗VEGF治疗;视力较好且离诊所较远的患者更可能转至其他诊所继续治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To explore the factors and frequency of interruptions in intravitreal treatment for patients with neovascular age-related macular degeneration (AMD) and to evaluate the demographic and clinical factors linked to the reasons for discontinuation. METHODS: In this multicentre study, patients who began anti-vascular endothelial growth factor (VEGF) treatment between January 2019 and December 2021 for treatment-naïve neovascular exudative AMD were retrospectively analysed. The overall incidence of treatment discontinuation, along with the rates for each specific cause, was calculated. The probability of each cause of discontinuation over time from the start of treatment, as well as the risk factors associated with each case, was also determined. RESULTS: 655 individuals (28.5%) discontinued intravitreal anti-VEGF therapy. Among the five main categories of causes for discontinuation (patient's decision against clinician's advice, continuation of therapy at another clinic, clinical decision, systemic diseases or death), clinical decision emerged as the most common reason for interruption. The qualitative evaluation of the Kaplan-Meier curves suggests a higher frequency of the clinical decision as a cause of discontinuation within the initial 2 years of treatment. Worse visual acuity increased the risk of discontinuation due to clinical decisions. Younger patients were more likely to stop anti-VEGF therapy by choice. Better visual acuity and longer distance from the clinic increased the likelihood of patients continuing treatment elsewhere. CONCLUSIONS: The discontinuation of anti-VEGF treatment is common among individuals with neovascular AMD. Causes of discontinuation include not only clinician decisions but also those related to the patient's health and personal choices.

来源:Br J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Borrelli E, Foti C, Ulla L, et al. Incidence and reasons for discontinuation of anti-VEGF treatment in neovascular age-related macular degeneration. Br J Ophthalmol. 2025. PMID: 40122580. doi:10.1136/bjo-2024-326152

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。